StagePIPE - II | IPO
About Alaunos Therapeutics
Alaunos Therapeutics (NASDAQ: TCRT) is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of in-licensed cancer drugs to address unmet medical needs. The company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for patient treatment. Alaunos Therapeutics was formerly known as Alaunos Therapeutics. It was founded in 2003 and is based in Boston, Massachusetts.
Missing: Alaunos Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Alaunos Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Alaunos Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Alaunos Therapeutics is included in 1 Expert Collection, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Alaunos Therapeutics Patents
Alaunos Therapeutics has filed 11 patents.
Transcription factors, Antineoplastic drugs, Sesquioxides, Oncology, Experimental cancer drugs
Transcription factors, Antineoplastic drugs, Sesquioxides, Oncology, Experimental cancer drugs
Latest Alaunos Therapeutics News
Apr 28, 2023
News Provided By Share This Article Neoantigens Market valued at US$ 2,71,428.57 thousand in 2023 and projected to reach US$ 10,54,783.54 thousand by 2028 with CAGR of 31.2% from 2023 to 2028 NEW YORK, UNITED STATES, April 28, 2023 / EINPresswire.com / -- The Insight Partners Latest Research on " Neoantigens Market Forecast to 2028" Includes COVID-19 Impact and Global Analysis By Treatment (Combination Therapy and Mono Therapy) and Therapeutic Specialty (Gastrointestinal Cancer, Lung Cancer, Solid Tumor, Urinary Systems Cancers, Melanoma, Head and Neck Cancer, and Others) Neoantigens are recently developed antigens that have not been detected by the immune system historically. Alterations in tumor proteins may result in the development of neoantigens caused by mutations or viral proteins. Neoantigens are used in selective treatments for cancerous cells. Download PDF Sample Copy at: https://www.theinsightpartners.com/sample/TIPRE00021781/ The market is expected to grow due to the key factors such as developments in neoantigen vaccines against cancer and increasing prevalence of cancer. However, the possible side effects associated with neoantigen vaccines are expected to restraint the growth of the market during the forecast years. The report highlights the trends prevalent in the market and the factors driving the market along with those that act as restraints to its growth. The growth of the market is attributed to some key driving factors such as developments in neoantigen vaccines against cancer and increasing prevalence of cancer. However, the possible side effects associated with neoantigen vaccines are expected to restraint the growth of the market during the forecast years. Leading Companies Analysis: The most notable market participants are Achilles Therapeutics plc, Advaxis, Inc., Frame Cancer Therapeutics, Genocea, Gradalis, Inc., Gritstone Oncology, Immunicum AB, Medigene AG, Ziopharm Oncology, Inc., and Moderna, Inc. among others, occupying a considerable share of the market owing to their offerings to the market. Many biotechnology companies are involved in the development of neoantigens, and most of them are in the clinical and pre-clinical phases of development. As per the data obtained from ClinicalTrials.gov, many clinical studies have been completed and moved on to the next stage of clinical trials in the US and other countries. For instance, Phase 1 study of ADXS-NEO is an antigen delivery product developed by Advaxis to identify neoantigens is under Phase 1 of clinical trials. Furthermore, Genocea Biosciences, Inc. is evaluating a personalized adjuvant vaccine, GEN-009 Neoantigen Vaccine, for the treatment of patients with solid tumors. Currently, the candidate is in a Phase 1/2a clinical trial. With the assumption of the probable commercial availability of neoantigen for clinical treatment in 2023. Analyzing this, the market has been forecasted from 2023 to 2028. Have a Call with Analyst: Prominent players in neoantigens market are focusing on majorly on inorganic strategies such as signing of agreements, and collaborations to garner their significance and remain competitive in the market. Few of the important key developments from the industry are mentioned below: Apr-2021: Immunicum has announced the start of a research partnership with Nina Bhardwaj's laboratory at the Tisch Cancer Institute's Icahn School of Medicine at Mount Sinai in New York City. Bhardwaj is the Director of Immunotherapy and Medical Director of the Vaccine and Cell Therapy Core Facility Apr-2020: Frame Therapeutics and eTheRNA immunotherapies NV have established a new research partnership to create mRNA cancer vaccines against immunogenic neoantigens May-2019: Ziopharm announced an exclusive licence arrangement with the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), for intellectual property relating to the production and commercialization of cancer cell therapies Market Segmentations: Based on treatment, the neoantigens market is segmented into combination therapy and mono therapy. In 2023, the combination therapy segment is estimated to have a larger market share, whereas the mono therapy segment is expected to have a faster growth during the forecast period. Based on therapeutic specialty, the neoantigens market is segmented into gastrointestinal cancer, lung cancer, solid tumor, urinary systems cancers, melanoma, head and neck cancer, and others. In 2023, the gastrointestinal cancer segment is estimated to hold the largest share of the market and is expected to grow at the fastest rate during the coming years. Major primary and secondary sources referred to while preparing the report on the neoantigens market are American Association for Cancer Research, Cancer Association of South Africa, European Medicines Agency, The Food and Drug Administration, Institute for Research in Immunology and Cancer – Commercialization of Research, and the World Health Organization, among others. Buy Report at: https://www.theinsightpartners.com/buy/TIPRE00021781/ About The Insight Partners: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Sameer Joshi
Alaunos Therapeutics Frequently Asked Questions (FAQ)
When was Alaunos Therapeutics founded?
Alaunos Therapeutics was founded in 2003.
Where is Alaunos Therapeutics's headquarters?
Alaunos Therapeutics's headquarters is located at One First Avenue, Boston.
What is Alaunos Therapeutics's latest funding round?
Alaunos Therapeutics's latest funding round is PIPE - II.
Who are the investors of Alaunos Therapeutics?
Investors of Alaunos Therapeutics include LBi International, ProQuest Investments, Panacea Asset Management, Medical Strategy, Millennium Management and 36 more.
Who are Alaunos Therapeutics's competitors?
Competitors of Alaunos Therapeutics include Gelesis, Tizona Therapeutics, MOgene LC, Celator Pharmaceuticals, Jennerex Biotherapeutics, Telormedix, aFraxis, Merrimack Pharmaceuticals, HealOr, Pivotal Biosciences and 13 more.
Compare Alaunos Therapeutics to Competitors
Pivotal BioSciences, Inc. is a company focused on the development and commercialization of cancer therapies.
BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.
Immunservice is a biopharmaceutical company addressing orphan disease indications as well as large market indication areas, especially those of high unmet medical need.Immunservice's biomimetic approach translates human immune hormones into well tolerated and highly effective marketable drugs that improve survival and quality of life in patients.Biomimetic therapy has the clear potential to cure patients with cancer, even those who are in urgent need and have little or no treatment alternatives.
ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.
Anaborex Anaborex is an early stage biotechnology company developing drugs for the treatment of the wasting syndrome many cancer patients experience towards the late stages of their disease.
CELLective Dx is an early-stage company developing a new generation of diagnostic tools for cancer based on analysis of CTCs directly from a patient's blood. Our novel proprietary technologies combine microfluidics, flow dynamics, cell biology, molecular biology, biochemistry, and surface chemistry to capture and analyze rare CTCs in blood more rapidly and effectively than other current technologies. CELLective Dx is developing simple, rapid, blood-based cancer tests that will provide physicians and patients with accurate and individualized clinical information on disease status, treatment selection, and treatment response that will dramatically improve the clinical management of cancer.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.